ClinicalTrials.gg
RecruitingNCT05416307Updated Oct 13, 2026

Open-label Study of ELA026 in Participants With Secondary Hemophagocytic Lymphohistiocytosis (sHLH)

A Phase 2/3 interventional study of ELA026 in Secondary Hemophagocytic Lymphohistiocytosis (sHLH), sponsored by Electra Therapeutics Inc.. Recruiting at 42 sites in 7 countries. Open to participants aged 6 Years and older. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by Electra Therapeutics Inc. · Phase 2/3, Interventional, and Treatment

From the registry’s dates

  • Started May 2022; still recruiting 4 years 5 months later.
Updated Oct 13, 2026Site recruiting status changedPrimary completion moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
156
Allocation
Non-randomized
Ages
6 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 42 studies in Lymphohistiocytosis, Hemophagocytic with a site in United States — 11 open to participants now, 19 under way, 1 of them phase 3. Lymphohistiocytosis, Hemophagocytic · United States.

Planned enrollment
Largest of 32
156 · median 21
Started
2022
the only one that year
Phase 2/3
5 of 42
1 open now
Primary completion
2028-03
later than 10 of 18 live
Registered
35th of 42
by date

Among the 42 studies in Lymphohistiocytosis, Hemophagocytic with a site in United States, this one has the largest planned enrollment of the 32 interventional ones that give a count, is the only one that started in 2022, is one of 5 in phase 2/3, reaches primary completion later than 10 of the 18 other live ones, and was the 35th registered.

Lymphohistiocytosis, Hemophagocytic

111 studies on the registry are indexed under Lymphohistiocytosis, Hemophagocytic; 41 are open to participants now.

Browse Lymphohistiocytosis, Hemophagocytic studies →

Open to participants now

11 of the 42 studies in Lymphohistiocytosis, Hemophagocytic with a site in United States are open now. Recruiting first, the newest first:

5 more — sign in →

All 11 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 26 Lymphohistiocytosis, Hemophagocytic studies recruiting now, 14 (54%) set no upper age limit and 8 (31%) stop at 75 or younger; 15 take children under 18; 2 take healthy volunteers.

This study: 6 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 42 studies in Lymphohistiocytosis, Hemophagocytic with a site in United States, or all of them as a file.
02

Study summary

Hemophagocytic lymphohistiocytosis is a rare, aggressive and life-threatening syndrome of excessive immune activation. Secondary hemophagocytic lymphohistiocytosis (sHLH) is the most common form of this disease and is typically associated with several other clinical conditions (eg, malignancy associated HLH (mHLH), infection, or autoimmune disease). ELA026 is a fully human immunoglobulin G1 (IgG1) signal regulatory protein (SIRP)-directed monoclonal antibody designed to deplete the myeloid and T cells driving the inflammation. The purpose of this study is to assess the safety, efficacy pharmacokinetics and pharmacodynamics of ELA026 in participants with sHLH.

Read the detailed description

This study consists of two parts: Phase 1b (Part 1) and Phase 2/3 (Part 2).

Part 1 is designed to evaluate the safety, efficacy, pharmacodynamics, and pharmacokinetics of ELA026 in pediatric and adult participants with treatment-naïve (TN) and relapsed/refractory sHLH. The main objectives of Part 1 are to determine the safety of ELA026 administered intravenously (IV) and subcutaneously (SC) to participants with sHLH and to identify the recommended Phase 3 dose and schedule for ELA026. Participants will be enrolled into a dose-escalating cohort (Cohort 1) followed by two fixed dose cohorts (Cohorts 2-3) treated over 12-weeks.

Part 2 (SURPASS) is designed as an open-label, single-arm, multicenter, historical control registrational study to evaluate ELA026 in newly diagnosed TN adult and pediatric sHLH participants. All participants are diagnosed with HLH-2004 criteria unless indicated. Cohort A (primary cohort) will enroll newly diagnosed TN participants ≥18 years old with mHLH. Cohort B (exploratory cohort) will enroll participants including ≥18 years old participants with TN sHLH not triggered by malignancy; ≥18 years old participants with newly diagnosed TN mHLH diagnosed by biomarker criteria but not meeting HLH-2004 diagnostic criteria; and 6 to 17 year old participants with newly diagnosed TN sHLH (due to any trigger). For 6 to 12 year old participants, there is a safety lead-in cohort with refractory sHLH.

Part 1 is closed to recruitment and Part 2 is recruiting for eligible participants.

03

Conditions studied

  • Secondary Hemophagocytic Lymphohistiocytosis (sHLH)
04

Who can participate

The criteria were revised on the registry on Oct 13, 2026. See what changed

Ages eligible
6 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria for Part 1:

  1. ≥12 years at the time of HLH diagnosis (Cohort 1).
  2. ≥6 years at the time of HLH diagnosis (Cohort 2-3).
  3. Treatment naïve or (Cohorts 1 and 2).
  4. Treatment naïve or early refractory (Cohort 3).
  5. Participant with sHLH confirmed criteria based on fulfilling 5 out of 8 HLH-2004 diagnostic criteria.

Key Inclusion Criteria for Part 2:

  1. Cohort A: Adults with newly diagnosed, treatment-naïve, -associated sHLH.
  2. Cohort B: Adults with newly diagnosed, treatment-naïve, non-malignancy-associated sHLH.
  3. Cohort B: Adults with newly diagnosed, treatment-naïve, malignancy-associated sHLH, diagnosed by OHI index.
  4. Cohort B: 13 to 17 years olds with newly diagnosed, treatment-naïve sHLH.
  5. Cohort B: 6 to 12 year olds, with refractory sHLH (safety lead-in cohort).
  6. Cohort B: 6 to 12 year olds, with newly diagnosed, treatment-naïve sHLH (after completion of safety lead-in cohort).

Key Exclusion Criteria for Part 1:

  1. Known or previous treatment for primary HLH
  2. Any other significant concurrent, uncontrolled medical condition that in the opinion of the Investigator contraindicates participation in this study
  3. Unknown trigger for sHLH
  4. Active, relapsed/refractory malignancy for which no suitable therapies are available to treat the malignancy triggering the HLH
  5. Allogeneic hemopoietic stem cell transplant () within 100 days of the first dose of ELA026.
  6. Ongoing administration of any therapies used to treat HLH (excluding dexamethasone)
  7. Live or attenuated vaccine received within 6 weeks or bacille Calmette-Guerin (BCG) vaccine within 12 weeks prior to Screening

Key Exclusion Criteria for Part 2:

  1. Refractory sHLH (except for the safety lead-in cohort for 6-12 year olds in Cohort B).
  2. Known or suspected primary or hereditary HLH.
  3. Severe organ dysfunction.
  4. Any other significant concurrent, uncontrolled medical condition that contraindicates participation in this study or prohibits completion of study procedures.
  5. End-stage malignancy for which no suitable therapies are available to treat the malignancy triggering the HLH.
  6. Allogeneic hemopoietic stem cell transplant within 30 days prior to enrollment.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
156 participants (estimated)

Study arms

  • Experimental
    Part 1 ELA026

    Cohort 1: Single dose escalation up to 3.0 mg/kg IV or SC. Cohort 2: priming dose: 0.1 mg/kg IV on Day 1; 0.3 mg/kg IV on Day 2 - 4, followed by weekly maintenance doses of 1 mg/kg IV/SC from Day 8 to Day 81. Cohort 3: priming dose: 0.1 mg/kg IV on Day 1; 0.3 mg/kg IV on Days 2 - 4, followed by twice weekly maintenance doses of 0.5 mg/kg IV/SC from Day 8 to Day 81.

    Drug: ELA026

  • Experimental
    Part 2 ELA026

    Cohort A and Cohort B: priming dose: 0.1 mg/kg IV/SC on Day 1; loading dose 0.3 mg/kg IV/SC on Days 2 - 4, followed by twice weekly maintenance doses of 0.5 mg/kg (IV/SC) from Day 8 to Day 81.

    Drug: ELA026

Interventions

  • DrugELA026

    Multiple doses of ELA026

06

What researchers measure

Primary outcomes

  1. Part 1: Number of Participant with Incidence of Treatment-Emergent Adverse Events (TEAEs) [Safety and tolerability]

    Incidence of adverse events (AEs) including dose-limiting toxicities (DLTs), serious adverse events (SAEs), deaths, AEs leading to withdrawal from study

    Time frame: Up to Week 12

  2. Part 2 (Cohort A): 56-day Survival Rate in Participants with mHLH and Have Lymphoma as the Cancer Trigger

    Time frame: 56 days

Secondary outcomes

  1. Number of Participants Achieving Early Survival (Cohort A)

    Time frame: up to 90 days

  2. Number of Participants Achieving HLH Disease Response by Day 29 (Cohort A)

    HLH disease response includes achievement of CR, mCR, PR, or HI.

    Time frame: Up to Day 29

  3. Number of Participants with TEAEs (Cohort A)

    Time frame: Up to Week 12

07

Study locations

32 of 42 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started May 2022 (actual). Primary completion is estimated for Mar 2028, 70 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 13, 2026: primary completion Jun 2027 → Mar 2028 and completion Jun 2029 → Mar 2030.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 6, 2022
First posted
Jun 13, 2022
StartActual
May 19, 2022
Primary completionEst.
Mar 2028was Jun 2027
CompletionEst.
Mar 2030was Jun 2029
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added. 2 sites changed recruiting status (2 now completed)
Show 2 sites
  • Phoenix Children's Hospital · Phoenix, United StatesActive, not recruiting→Completed
  • University of California, Los Angeles · Los Angeles, United StatesActive, not recruiting→Completed
Show site
  • University of Texas Southwestern Medical Center · Dallas, United States
Oct 13, 2026
Primary completion
Jun 2027→Mar 2028
Oct 13, 2026
Study completion
Jun 2029→Mar 2030
Oct 13, 2026
Eligibility
1 criterion edited
What changed in the criteria
  • EditedAllogeneic hemopoietic stem cell transplant within 10030 days prior to the first dose of ELA026enrollment.
Oct 13, 2026
Secondary outcomes
1 edited
What changed in the outcomes
  • EditedNumber of Participants with TEAEs (Cohort A)Time frame: Up to Week 12
Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    1 site added. 2 sites changed recruiting status (2 now completed)
    Show 2 sites
    • Phoenix Children's Hospital · Phoenix, United StatesActive, not recruiting→Completed
    • University of California, Los Angeles · Los Angeles, United StatesActive, not recruiting→Completed
    Show site
    • University of Texas Southwestern Medical Center · Dallas, United States
    Primary completion Jun 2027→Mar 2028
    Study completion Jun 2029→Mar 2030
    Eligibility 1 criterion edited
    What changed in the criteria
    • EditedAllogeneic hemopoietic stem cell transplant within 10030 days prior to the first dose of ELA026enrollment.
    Secondary outcomes 1 edited
    What changed in the outcomes
    • EditedNumber of Participants with TEAEs (Cohort A)Time frame: Up to Week 12
    + 2 other changes: verification date and arm descriptions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05416307
Lead sponsor
Electra Therapeutics Inc.
Responsible party
Sponsor
First posted
Jun 13, 2022
Start date
May 19, 2022
Primary completion
Mar 2028 (estimated)
Completion
Mar 2030 (estimated)
Last update
Oct 13, 2026

Study contacts

Clinical Trials
Contact
clinicaltrials@electra-therapeutics.com
Please email
Medical Director
study director · Electra Therapeutics Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ipsoprubart

Start the discussion